Disease, Diagnoses, and Dollars

Disease, Diagnoses, and Dollars

EnglishHardback
Kaplan Robert M.
Springer-Verlag New York Inc.
EAN: 9780387740447
On order
Delivery on Friday, 3. of January 2025
CZK 566
Common price CZK 629
Discount 10%
pc
Do you want this product today?
Oxford Bookshop Praha Korunní
not available
Librairie Francophone Praha Štěpánská
not available
Oxford Bookshop Ostrava
not available
Oxford Bookshop Olomouc
not available
Oxford Bookshop Plzeň
not available
Oxford Bookshop Brno
not available
Oxford Bookshop Hradec Králové
not available
Oxford Bookshop České Budějovice
not available
Oxford Bookshop Liberec
not available

Detailed information

Disease, Diagnoses, and Dollars is about the costs of health care and their impact on health. The U.S. health care system is the largest sector in the biggest economy, and the US spends significantly more per capita on health care than any other country, yet it ranks last among comparison nations on the major health indicators. Within the U.S., there is evidence that regions that spend more do not have better outcomes, and some evidence suggests that quality of care is lower in the regions that spend more, not less, on health care.

Robert Kaplan takes the controversial position that mass markets have been created for services that may offer little or no benefit to patients. Many of these markets are for preventive medicine, making healthy people a market for expensive pharmaceutical products and tests. These include cancer screening tests and medications to control blood pressure, cholesterol, and glucose. Kaplan forcefully argues that the overuse of medications and tests runs up the costs of health care. As more employers drop health insurance for their employees when costs accelerate, the expanded use of ineffective preventive medicine may have the unintended consequence of increasing the number of uninsured patients, potentially damaging the health of others in the community.

The concluding chapters of Disease, Diagnoses, and Dollars offer suggestions for policy makers and for patients. Methods for systematically evaluating the cost-effectiveness of new guidelines are discussed. The final chapter provides practical suggestions to enable patients to share in decisions about treatments or tests that can have uncertain benefits.

EAN 9780387740447
ISBN 0387740449
Binding Hardback
Publisher Springer-Verlag New York Inc.
Publication date December 19, 2008
Pages 190
Language English
Dimensions 235 x 155
Country United States
Authors Kaplan Robert M.
Illustrations 81 Illustrations, black and white; XVIII, 190 p. 81 illus.
Edition 2009